Please login to the form below

Not currently logged in
Email:
Password:

Activartis

This page shows the latest Activartis news and features for those working in and with pharma, biotech and healthcare.

FDA grants orphan status to Activartis’ brain cancer immunotherapy

FDA grants orphan status to Activartis’ brain cancer immunotherapy

Activartis' AV0113 is part of this growing trend, and the drug has shown promise in early-stage trials. ... time. According to Activartis, preliminary results revealed a “very promising trend” towards overall survival benefit in patients taking AV0113

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics